Novo Nordisk shares fell in early Monday trading in Copenhagen after reports emerged that the company's blockbuster weight-loss and diabetes drugs have been added to China's National Essential Medicines List.
The listing, which includes semaglutide—the active ingredient in Ozempic and Wegovy—marks a significant regulatory development for the world's most valuable pharmaceutical company.
The National Essential Medicines List is a government-curated roster of drugs deemed vital for public health.
Inclusion typically grants broader access through the national healthcare system but often comes with stringent price negotiations and reimbursement caps.
For Novo Nordisk, this move suggests that Beijing is preparing to integrate its high-demand obesity treatments into the state-funded framework, likely at a lower price point than currently charged in the open market.
This development adds to a week of volatility for the Danish pharma giant.